Every material Form 8-K PDS Biotechnology Corp has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
PDS Biotechnology filed an 8-K on October 20, 2026 to report that it updated its corporate presentation deck, which is attached as Exhibit 99.1. The filing contains no new financial results, guidance, or transaction terms, and the deck's clinical figures are company-presented and preliminary.
Corporate presentation (October 2026) filed as Exhibit 99.1 on October 20, 2026.
Deck cites a 71.4% objective response rate at six months in an NCI-led Phase 2 trial of PDS0301 plus chemotherapy in colorectal cancer with liver metastases; the company notes the trial was not randomized.
Deck lists five PDS0301 data readouts expected between Q4 2026 and Q2 2028.
Deck states more than 380 patients have been dosed across PDS0301 and PDS0101 trials.
PDS Biotechnology reported that four directors resigned from its Board effective October 18, 2026, and the Board appointed three new directors that day to fill three of the four vacancies. The Board fixed its size at seven directors and reconstituted its committees, which matters to shareholders because it changes who oversees audit, compensation and governance.
Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned effective October 18, 2026; the filing says none resulted from a disagreement with the Company.
Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel were appointed directors on October 18, 2026, and the Board set its size at seven.
Each new director received a nonqualified stock option to purchase 22,700 shares, vesting in three annual installments.
James Banaag chairs the Audit Committee and is designated an audit committee financial expert; Bruce Wendel chairs the Nominating and Corporate Governance Committee.
PDS Biotechnology announced a virtual key opinion leader event on October 15, 2026, at 8:00 AM ET. Investigator Jonathan M. Hernandez, M.D., of the National Cancer Institute, will join management to discuss clinical outcomes from the PDS0301 Phase 2 trials, focusing on metastatic colorectal cancer. The filing reports no financial results, so the event itself is the news for shareholders.
Virtual KOL event is set for Thursday, October 15, 2026, at 8:00 AM ET, followed by a live question and answer session
Speaker is Jonathan M. Hernandez, M.D., Investigator, Surgical Oncology Program, NCI Center for Cancer Research
Discussion covers PDS0301 Phase 2 clinical outcomes, with a focus on the metastatic colorectal cancer (mCRC) cohort
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PDS Biotechnology Corp filing is on SEC EDGAR ↗. 8-K briefs of other companies →